Neil Gibson Net Worth

The estimated Net Worth of Neil W Gibson is at least $2.09 Million dollars as of 28 November 2014. Neil Gibson owns over 2,500 units of TCR2 Therapeutics stock worth over $122,100 and over the last 12 years he sold TCRR stock worth over $1,968,828. In addition, he makes $0 as Independent Director at TCR2 Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Neil Gibson TCRR stock SEC Form 4 insiders trading

Neil has made over 10 trades of the TCR2 Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 79,640 units of TCRR stock worth $524,828 on 7 November 2019.

The largest trade he's ever made was selling 80,000 units of TCR2 Therapeutics stock on 28 January 2015 worth over $1,444,000. On average, Neil trades about 8,928 units every 95 days since 2012. As of 28 November 2014 he still owns at least 82,500 units of TCR2 Therapeutics stock.

You can see the complete history of Neil Gibson stock trades at the bottom of the page.

Neil Gibson biography

Dr. Neil W. Gibson Ph.D. serves as Independent Director of the Company. Dr. Gibson has served on our board of directors since February 2018. Since 2016, he has served as Senior Vice President to COI Pharmaceuticals, Inc. and President and CEO of PDI Therapeutics. From 2015 to 2016, Dr. Gibson served as Senior Vice President and Chief Development Officer to BioAtla LLC. From 2011 to 2015, he served as Chief Scientific Officer of Regulus Therapeutics Inc., and from 2007 to 2011 he was Chief Scientific Officer of Pfizer Oncology based in La Jolla, CA. Dr. Gibson received his Ph.D. from the University of Aston and his B.Sc. from the University of Strathclyde. Gibson is qualified to serve on our board of directors because of his extensive experience in the life sciences industry.

How old is Neil Gibson?

Neil Gibson is 63, he's been the Independent Director of TCR2 Therapeutics since 2018. There are no older and 16 younger executives at TCR2 Therapeutics.

What's Neil Gibson's mailing address?

Neil's mailing address filed with the SEC is C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN, TX, 78701.

Insiders trading at TCR2 Therapeutics

Over the last 6 years, insiders at TCR2 Therapeutics have traded over $15,820,150 worth of TCR2 Therapeutics stock and bought 4,788,512 units worth $65,684,711 . The most active insiders traders include Group, Llc Green Jeremy Red..., Kevin Ctang Capital Managem..., and Ansbert Gadicke. On average, TCR2 Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of $229,829. The most recent stock trade was executed by Kevin Ctang Capital Managem... on 25 May 2023, trading 50,000 units of TCRR stock currently worth $86,000.

What does TCR2 Therapeutics do?

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Complete history of Neil Gibson stock trades at Regulus Therapeutics Inc, TCR2 Therapeutics, and Shattuck Labs

TCR2 Therapeutics executives and stock owners

TCR2 Therapeutics executives and other stock owners filed with the SEC include:

• Garry Menzel,
  President, Chief Executive Officer, Director
• Alfonso Cardama,
  Chief Medical Officer
• Mayur Somaiya,
  Chief Financial Officer
• Dr. Garry E. Menzel M.B.A., Ph.D.,
  Pres, CEO & Director
• Dr. Alfonso Quintás Cardama M.D.,
  Chief Medical Officer
• Mayur Amrat Somaiya,
  Chief Financial Officer
• Dr. Patrick A. Baeuerle Ph.D.,
  Founder & Member of the Advisory Board
• Carl Mauch,
  IR Contact Officer
• Stephen Webster,
  Independent Director
• Neil Gibson,
  Independent Director
• Andrew Allen,
  Independent Director
• Axel Hoos,
  Director
• Patrick Baeuerle,
  Director
• Robert Hofmeister,
  Chief Scientific Officer
• Angela Justice,
  Chief People Officer
• Ansbert Gadicke,
  Independent Chairman of the Board
• Dr. Rosemary Harrison Ph.D.,
  Chief Bus. & Strategy Officer
• Dr. Robert Hofmeister Ph.D.,
  Chief Scientific Officer
• Stephen Turkowiak M.B.A.,
  VP of Fin. & Treasurer
• Gregg McConnell M.B.A.,
  Head of Bus. Devel.
• Dr. Angela Justice Ph.D.,
  Chief People Officer
• Margaret Siegel J.D.,
  VP & Head of Legal & Corp. Sec.
• Peter Olagunju,
  Chief Technical Officer
• Eric Sullivan,
  Chief Financial Officer
• Oncology Impact Fund L.P.On...,
  
• Morana Globeways Holdings L...,
  
• Morana Globeways Holdings I...,
  
• Morana Globeways Holdings L...,
  
• Morana Globeways Holdings L...,
  
• Oncology Impact Fund L.P.On...,
  
• Morana Globeways Holdings L...,
  
• Investment Ltd China Molybd...,
  
• Sun States Fund, L.P.Mpm As...,
  
• Group, Llc Green Jeremy Red...,
  
• Bio Ventures 2014, L.P.Fole...,
  
• Shawn Tomasello,
  Director
• Peter Olagunju,
  Chief Operating Officer
• Priti Hegde,
  Director
• Rosemary Harrison,
  Chief Business & Strategy
• Kevin Ctang Capital Managem...,
  
• Asset Management Llcevnin L...,